Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 8/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16833198 | 0.91 | NQO2 (0.49) | NQO2KDM4EPLA2G2ANR4A2ABL1 | |
| SCHEMBL16832963 | 0.87 | NQO2 (0.59) | NQO2KDM4ECHEK1PLA2G2ANR4A2 | |
| SCHEMBL29199787 | 0.86 | KDM4E (0.46) | KDM4ECHEK1PLA2G2ANR4A2ABL1 | |
| SCHEMBL2905571 | 0.86 | NQO2 (0.42) | NQO2KDM4EPLA2G2ANR4A2 | |
| SCHEMBL26632820 | 0.84 | NQO2 (0.41) | NQO2KDM4EPLA2G2A | |
| SCHEMBL26632794 | 0.83 | NQO2 (0.40) | NQO2KDM4EPLA2G2A | |
| SCHEMBL16832379 | 0.80 | ADORA2A (0.47) | NQO2KDM4EPLA2G2A | |
| SCHEMBL28100406 | 0.79 | NQO2 (0.53) | NQO2KDM4EPLA2G2A | |
| SCHEMBL29199714 | 0.79 | PSMD14 (0.49) | KDM4EPLA2G2ANR4A2ABL1 | |
| SCHEMBL16832419 | 0.78 | NQO2 (0.53) | NQO2KDM4EPLA2G2ANR4A2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | NQO2 338/4885KDM4E 3458/4885CHEK1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.